TPST (Tempest Therapeutics) Other Financing: $3.31 Mil (TTM As of Mar. 2026)


TPST Tempest Therapeutics Inc TPST
32 GF Score
Price $1.12
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Other Financing?

Tempest Therapeutics TPST 32 Other Financing is $3.31 Mil as of Mar. 2026. GuruFocus rates TPST with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Tempest Therapeutics's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

Tempest Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $3.31 Mil.

Tempest Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Tempest Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics Other Financing Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 10.64 0.00 0.00 0.31 3.36

Tempest Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 1.86 0.00 1.45 0.00
TPST
32GF Score
Tempest Therapeutics Inc TPST
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $3.31 Mil mean?
Tempest Therapeutics (TPST) has a Other Financing of $3.31 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Tempest Therapeutics and its competitors.
Is Tempest Therapeutics' Other Financing too high?
Tempest Therapeutics' current Other Financing is $3.31 Mil. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Other Financing compare to HOWL and INTI?
Tempest Therapeutics' Other Financing of $3.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Tempest Therapeutics and its competitors. Tempest Therapeutics's current Other Financing is $3.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current Other Financing of $3.31 Mil. The current Other Financing is $3.31 Mil. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current Other Financing is $3.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score

Get the complete analysis for TPST

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price